# Debiopharm Innovation Fund

> Debiopharm Innovation Fund is a VC fund backing Health Care and Biotechnology. See 47 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Lausanne, Switzerland
- Total investments: 47
- Last investment: Jun 2025
- Lead investor: 55%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/32979
- X (Twitter): https://twitter.com/debiopharmfund
- Website: https://www.debiopharm.com/digital-health/

Debiopharm Innovation Fund is a VC fund in Lausanne focused on Health Care and Biotechnology. Debiopharm Innovation Fund invests in digital health companies that have an impact on cancer, infectious diseases, and drug development. We are looking for ambitious entrepreneurs raising series A or B with clinically proven, transformative technologies that use AI and data to help patients. We do not invest in consumer wellness or workflowsolutions. Our initial investment is typically $2-5M. Along with capital we bring deep pharma knowledge & networks and long-term commitment to help build value in your company. We are an evergreen investment fund of the pharmaceutical company Debiopharm based in Lausanne, Switzerland.

## Contacts

5 contacts available for Debiopharm Innovation Fund. Shizune tracks 5 team members at Debiopharm Innovation Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/debiopharm-innovation-fund?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $943k–$6M |
| Pre-Seed | $317k–$1.7M |
| Series A | $3.5M–$25M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 18 | 38% |
| Biotechnology | 13 | 28% |
| Software | 10 | 21% |
| Life Science | 7 | 15% |
| Artificial Intelligence | 7 | 15% |

43 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 13 | 28% |
| Seed | 6 | 13% |
| Pre-Seed | 5 | 11% |
| Series B | 3 | 6% |
| Funding Round | 3 | 6% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 8 | 17% |
| Switzerland | 7 | 15% |
| France | 3 | 6% |
| United Kingdom | 3 | 6% |
| Israel | 2 | 4% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Cedric Odje | Senior Investment Associate | 15 | https://shizune.co/investors/profile/cedric-odje |
| Nicole Wilson | Senior Administrative Assistant | 0 | https://shizune.co/investors/profile/nicole-wilson-10b6 |
| Tanja Dowe | Chief Executive Officer | 8 | https://shizune.co/investors/profile/tanja-dowe |
| Thomas Gibbs | Director | 3 | https://shizune.co/investors/profile/tom-gibbs |
| Vincent Lepreux | Investment Principal | 5 | https://shizune.co/investors/profile/vincent-lepreux |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Octozi | AI agents to accelerate clinical development workflows for the pharma industry. |  | Pre-Seed | Jun 10, 2025 |  |
| MedaSystems | A cloud platform empowering global expanded and managed access programs. |  | Seed | Mar 05, 2025 |  |
| StratifAI | Building the next generation of biomarkers for precision oncology | $1.7M | Pre-Seed | Sep 02, 2024 |  |
| ViewsML | ViewsML leverages artificial intelligence to enhance virtual diagnostics and precision medicine. The company focuses on transforming spatial biology and translational research by utilizing virtual biomarkers. Their technology aims to improve patient outcomes by providing deeper insights into healthcare diagnostics. ViewsML is involved in developingimmunohistochemistry technology to streamline the diagnostic process and support research objectives efficiently. |  | Pre-Seed | Jun 14, 2024 |  |
| Risklick | Risklick is develops a first-of-the-kind data-driven tool to allow end-users to identify similar Clinical trials(CTs) and assess risks in early steps of the protocol design. CTs are used to determine the efficacy and safety of an experimental treatment; however, up to 90% of them fail in the early stage of protocol design and the nature andcomplexity of CTs make risk assessment difficult and time-consuming. |  | Seed | Apr 23, 2024 |  |
| Strategikon Pharma | Clinical Maestro™ by Strategikon Pharma is the only commercially available software platform for the end- to- end management of “clinical business operations”, which is the pharmaceutical industry vertical for planning, outsourcing and budgeting clinical trials. Biopharmaceutical companies outsource 90% of their clinical development pipelinespending billions of dollars engaging in highly complex outsourced relationships with thousands of global service providers, each using their own processes, systems and reporting structures. These sophisticated relationships require complex outsourcing strategies, demanding clinical financial planning, extensive sourcing due diligence and rigorous performance management. Currently the industry manages these activities in Excel, using labor intensive, inefficient processes, costing billions of dollars in infrastructure costs, regulatory non-compliance fines and delays to market. Clinical Maestro takes a radically different approach to the management of clinical portfolio through a transformative redesign of Excel-driven processes into end-to-end integrated workflows, breaking the communication and data integration siloes between pharma companies and their outsourcing partners. Clinical Maestro™ cases studies with leading pharmaceutical companies and CROs demonstrate savings of >80% vs. manual processes, >95% prediction accuracy for clinical study budgets and high user satisfaction and engagement. | $7M | Series A | Feb 06, 2024 |  |
| MedaSystems | A cloud platform empowering global expanded and managed access programs. |  |  | Jan 09, 2024 |  |
| MedaSystems | A cloud platform empowering global expanded and managed access programs. |  | Seed | Jan 09, 2024 |  |
| Concr | ConcR’s software integrates a breadth of data into a model to predict how and why a cancer therapy will behave |  | Seed | Nov 29, 2023 |  |
| OmicsChart | Patient-centric cancer data and analytics platform for translational cancer biologists | $317.4K | Pre-Seed | Oct 09, 2023 |  |

10 of 47 investments shown.

## Co-investors
- [Colorcon Ventures](https://shizune.co/investors/profile/colorcon-ventures) — VC Fund, 4 deals together
- [Cerner Capital](https://shizune.co/investors/profile/cerner-capital) — VC Fund, 3 deals together
- [Grove Ventures](https://shizune.co/investors/profile/grove-ventures) — VC Fund, 3 deals together
- [HLM Venture Partners](https://shizune.co/investors/profile/hlm-venture-partners) — VC Fund, 3 deals together
- [LRVHealth](https://shizune.co/investors/profile/long-river-ventures) — VC Fund, 3 deals together
- [Philips Health Technology Ventures](https://shizune.co/investors/profile/philips-health-technology-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [Reach Capital](https://shizune.co/investors/profile/reach-capital) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [GSV Ventures](https://shizune.co/investors/profile/gsv-acceleration) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Finland](https://shizune.co/investors/medical-vc-funds-finland)
- [Biotechnology VC Funds in Spain](https://shizune.co/investors/biotechnology-vc-funds-spain)
- [Health Care VC Funds in Finland](https://shizune.co/investors/health-care-vc-funds-finland)
- [EdTech Investors in Switzerland](https://shizune.co/investors/edtech-investors-switzerland)
- [EdTech VC Funds in Switzerland](https://shizune.co/investors/edtech-vc-funds-switzerland)
- [Life Science Investors in Spain](https://shizune.co/investors/life-science-investors-spain)

## FAQ

### What does Debiopharm Innovation Fund invest in?

Debiopharm Innovation Fund invests primarily in Health Care, Biotechnology and Software startups, most often at Series A and Seed stage. Most of the 47 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Debiopharm Innovation Fund's check size?

Debiopharm Innovation Fund typically joins rounds of $943k–$6M at Seed, $317k–$1.7M at Pre-Seed and $3.5M–$25M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Debiopharm Innovation Fund participates in.

### How do I contact Debiopharm Innovation Fund?

Public channels for Debiopharm Innovation Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Debiopharm Innovation Fund?

The team at Debiopharm Innovation Fund includes Cedric Odje (Senior Investment Associate), Nicole Wilson (Senior Administrative Assistant) and Tanja Dowe (Chief Executive Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co